ARTICLE | Company News
Deal streak continues for Alexion as Achillion’s story hits $930M high note
October 17, 2019 12:22 AM UTC
Updated on Oct 17, 2019 at 12:26 AM UTC
Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to build its pipeline beyond Soliris.
The takeout, announced Wednesday, would see Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquire Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) for $6.30 per share in cash, and give Alexion two complement inhibitors to supplement its leading position in paroxysmal nocturnal hemoglobinuria...